You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
機構密集調研 AI醫療賽道火熱
據中證報,今年以來超70家醫藥生物行業上市公司接受機構調研。值得一提的是,安必平、貝瑞基因、樂心醫療等公司被機構頻頻問及AI領域佈局情況、大模型研發進展及未來應用場景等相關問題。業內人士表示,AI能夠與醫療行業多個環節結合,極大程度地提高效率,降低成本,更好地配置研發和醫療資源。從應用端看,AI製藥、醫學影像、醫療信息化等領域展現出較大的應用潛力。截至發稿,今年以來接受機構調研頻次前十的醫藥生物公司中,安必平獲機構關注度最高,累計接受機構調研147家次;魚躍醫療、老百姓分居第二、第三位,接受機構調研頻次分別爲134家次、90家次;貝瑞基因、珍寶島、樂心醫療、盈康生命、邁威生物等緊隨其後,接受機構調研均在50家次以上。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.